Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3)

Drug Metab Lett. 2011 Apr;5(2):140-37. doi: 10.2174/187231211795305285.

Abstract

It is well known that nonsteroidal anti-inflammatory drugs (NSAIDs) delay the elimination of methotrexate. One of the mechanisms is thought to be inhibition of methotrexate uptake via human organic anion transporter 3 (hOAT3, SLC22A8) in the renal proximal tubule by NSAIDs. In this study, we evaluated the inhibitory effects of selective cyclooxygenase-2 inhibitor etoricoxib on hOAT3 by uptake experiments using Xenopus laevis oocytes. The injection of hOAT3 cRNA stimulated the uptake of methotrexate into the oocytes, and its transport was inhibited by etoricoxib. Etoricoxib inhibited estrone sulfate uptake by hOAT3 dose dependently, and the 50% inhibitory concentration was estimated to be 9.8 µM. Eadie-Hofstee plot analysis showed that etoricoxib inhibited hOAT3 in a competitive manner. These findings show that etoricoxib has inhibitory effect on hOAT3, and that the potential is comparable to that of traditional NSAIDs.

MeSH terms

  • Animals
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Etoricoxib
  • Humans
  • Methotrexate / metabolism
  • Organic Anion Transporters, Sodium-Independent / antagonists & inhibitors*
  • Pyridines / pharmacology*
  • Sulfones / pharmacology*
  • Xenopus laevis

Substances

  • Cyclooxygenase 2 Inhibitors
  • Organic Anion Transporters, Sodium-Independent
  • Pyridines
  • Sulfones
  • organic anion transport protein 3
  • Etoricoxib
  • Methotrexate